The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2025 | Evolving role of CAR-T and bispecifics in B-cell lymphoma: from R/R to frontline
Gloria Iacoboni, MD, PhD, Vall d’Hebron Institute of Oncology, Barcelona, Spain, discusses the impact of CAR T-cells and bispecific antibodies in the treatment of patients with aggressive B-cell lymphoma, particularly in the relapsed/refractory (R/R) setting. Dr Iacoboni highlights the promising results of ongoing trials and the potential for moving CAR T-cells into earlier lines, with studies exploring these agents in the frontline setting. This interview took place at the 13th Annual Meeting of the Society of Hematologic Oncology (SOHO 2025) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
